FREENOME HOLDINGS INC.

Company Overview

Freenome Holdings Inc. is developing multi-cancer detection systems utilizing multiomics, machine learning, and real-world data feedback loops. Its multi-omic platform combines proteomics, transcriptomics, genomics, and other omics to analyze both tumor and non-tumor signals. The company has partnered with several healthcare organizations to integrate its platform for simplified cancer detection. With over $1 billion raised from investors such as Google, Novartis, and Roche, Freenome secured an additional $254 million in financing in February 2024. This new funding, led by Roche, accelerated the development of its single and multi-cancer detection platforms.

Freenome Holdings Inc. is conducting the PREEMPT CRC Study to validate a blood-based colorectal screening test. The study spans over 200 sites in both urban and rural areas, enrolling more than 40,000 participants from diverse racial, ethnic, and socioeconomic backgrounds. With its methods and state-of-the-art technology, Freenome Holdings is set to majorly impact the future of colorectal cancer screening.

Company's Business Segments

• Clinical Research Services : The company provides a clinical research program that drives yearly cancer detection tests' development, discovery, and validation.